Oligonucleotide (siRNA) · Gene silencing: TMPRSS6 · developed by Silence Therapeutics
SLN124 is an RNA interference therapeutic made of small interfering RNAs conjugated to N-acetylgalactosamine, which binds asialoglycoprotein receptors on hepatocytes. Inside the liver cells, the siRNAs silence TMPRSS6 mRNA, reducing TMPRSS6 protein and allowing hepcidin levels to rise. It is studied in iron-related disorders and polycythemia vera.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05499013 | Phase 1/2 | Polycythemia Vera | Active not recruiting | SLN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Polycythemia Vera
Updated Nov 1, 2026. Something wrong or missing? Report it on the SLN page.
See SLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SLN catalysts and pipeline →